Key Developments: Terumo Corp (4543.T)
5,520JPY
22 May 2013
¥200 (+3.76%)
¥5,290
¥5,350
¥5,530
¥5,340
781,100
1,058,670
¥5,530
¥2,756
Latest Key Developments (Source: Significant Developments)
Terumo Corp to Sell Domiciliary Oxygen and Domiciliary Infusion Pump Business to AIR WATER INC
Terumo Corp announced that it has decided to sell its domiciliary oxygen and domiciliary infusion pump business, including its two subsidiaries, to AIR WATER INC, effective February 28, 2013. Full Article
Terumo Corp Announces Strategic Alliance with Chinese AngioCare in Renal Denervation Technology for Hypertension Treatment
Terumo Corp announced that a strategic alliance has been formed with Shanghai AngioCare Medical Technology Co., Ltd., which is a Chinese company in renal denervation technology for resistant hypertension treatment. Terumo will take on a 20% share in AngioCare. Furthermore, Terumo will consign product development to AngioCare and acquire the exclusive distribution rights for its renal denervation technology on the global market. Full Article
Biosensors International Group Ltd And Terumo Corporation Announces Extension Of Existing Licensing Agreements
Biosensors International Group Ltd and Terumo Corporation announced an extension of their existing licensing agreements, under which Terumo may continue to incorporate BioMatrix technology in the production, marketing and selling of Terumo's drug-eluting stent (DES) systems in markets worldwide, outside of the United States. Biosensors and Terumo have agreed to extend the original licensing agreement for territories outside of Japan until December 2014, under terms similar to the original October 2003 agreement. Terumo also continues to benefit from existing rights in Japan to manufacture, market and sell DES systems incorporating BioMatrix technology. Full Article
R&I Affirms Terumo Corp's Rating at "AA-"; Rating Outlook Negative
Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Terumo Corp at “AA-”. The rating outlook is negative. Full Article
Sony Corp, Olympus Corp To Agree To Capital Tie-up This Month; Terumo Corporation And FUJIFILM Holdings Corp. Seeks To Buy Stake In Olympus-Reuters
Reuters reported that Sony Corp is in the final stages of talks to invest JPY50 billion ($646 million) in Olympus Corp, with an agreement expected by the end of September, state broadcaster NHK reported. Olympus is in talks with Sony to accept a cash injection in return for a stake. Terumo Corporation and FUJIFILM Holdings Corp. have also said they are seeking to buy a stake in Olympus. Full Article
Terumo Corp Sues Olympus Corp Over Lost Shareholder Value-Reuters
Reuters reported that Terumo Corp had filed a lawsuit against Olympus Corp, seeking damages for lost shareholder value, and escalating a tussle with the endoscope maker over a tie-up proposal. Terumo said it would sue Olympus under Japan's Financial Instruments and Exchange Act for failing to disclose its accounting fraud before signing a business and capital tie-up with the medical equipment firm seven years ago. Terumo, which said the deadline for filing the suit was in early August, would not disclose the amount it sought for damages. Olympus was not available to comment. Full Article
Terumo Corporation Proposes Integration with Olympus Corp
Terumo Corporation announces that it has proposed a plan of integration with Olympus Corp. Terumo Corporation proposed to invest JPY 50 billion in Olympus Corp and to establish a holding company with Olympus Corp. Full Article
Terumo Corporation to Issue 3rd and 4th Series Unsecured Bonds
Terumo Corporation announced that it has decided to issue its third and fourth series unsecured bond. The Company will issue a JPY 40 billion third series unsecured bond, each with a face value of JPY 100 million, with an interest rate of 0.352% per annum. The bond will be matured on March 2, 2015. The Company will also issue a JPY 40 billion fourth series unsecured bond, each with a face value of JPY 100 million, with an interest rate of 0.504% per annum. The bond will be matured on March 2, 2017. The subscription date for both bonds is February 23, 2012 and the payment date is March 2, 2012. Nomura Securities Co., Ltd., Mizuho Securities Co., Ltd. and Goldman Sachs will be managing underwriters. Full Article
Terumo Corporation Establishes New Plant in Yamaguchi, Japan
Terumo Corporation announced that it has decided to establish a new plant in Yamaguchi, Japan, which will be engaged in the manufacturing of drug and medical device, to meet the increasing global demand. The Company invested JPY 30 billion in the new plant, which is expected to start operation since 2015. Full Article
Terumo Corporation's Subsidiary Acquires Onset Medical Corporation
Terumo Corporation announced that its subsidiary, Terumo Americans Holdings, Inc., has acquired all shares of Onset Medical Corporation and the large bore sheath technology. Full Article
Heart stent with new polymer matches Abbott top seller in study
- A drug-coated heart stent from Japan's Terumo Corp with a dissolving polymer proved just as effective as Abbott Laboratories' top-selling Xience stent at preventing a second procedure to clear the artery, a large study found.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
